Pilot protocol compares Ayurvedic Nimba-Amalakyadi powder versus metformin for type 2 diabetes
Last updated May 26, 2026
Key finding
This article is a pilot trial protocol in adults with newly diagnosed type 2 diabetes that plans to compare Nimba-Amalakyadi powder against metformin over 45 days, with follow-up to day 90, and no final efficacy results are reported yet.
This publication describes a planned pilot randomized open-label trial, not completed efficacy outcomes. It proposes enrolling 36 participants with type 2 diabetes to compare Nimba-Amalakyadi powder versus metformin for 45 days, with day-90 follow-up. The protocol emphasizes feasibility metrics and exploratory glycemic trends, but final comparative results are not available in this article.
Quick read
Study at a glance
The essential study design details in one scan.
EvidenceScore™
Low
Study type
Randomized Controlled Trials (RCTs)
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Save research, organize studies, and quickly find important evidence again.
Plain-language summary
What this paper says
A plain-language read of the study’s main message and where it applies.
Study focus
This article is a pilot trial protocol in adults with newly diagnosed type 2 diabetes that plans to compare Nimba-Amalakyadi powder against metformin over 45 days, with follow-up to day 90, and no final efficacy results are reported yet.
Published in
Journal Reference
Publication details and source links for this paper.
Sawarkar P, Sawarkar GR. Evaluation of the comparative efficacy of an Ayurvedic formulation (Nimba-Amalakyadi powder) vs metformin in the management of type 2 diabetes mellitus: protocol for a pilot study. JMIR Res Protoc. 2026;15:e63574. doi:10.2196/63574
Main Effects
No completed comparative efficacy results reported in this protocol publication
Planned glycemic endpoints include HbA1c, fasting blood sugar, postprandial glucose, and urine sugar
Feasibility endpoints include recruitment, retention, adherence, acceptability, and data completeness
Evidence Suggest
- Methods section specifies randomized allocation with two groups and 45-day intervention exposure plus day-90 follow-up.
- The paper explicitly identifies itself as a protocol and states final results are expected after completion phases.
- Outcome variables are described as planned measurements rather than reported comparative endpoint results.
Who this applies to
Adults aged 20-60 years with newly diagnosed type 2 diabetes (<6 months)
Keep in Mind
Interpret this as a protocol, not a completed efficacy trial.
Between the Lines
- This publication is a protocol and does not report final efficacy results.
- Small planned pilot sample size (n=36) limits inferential strength.
- Open-label design may introduce performance and expectation biases.
- Single-center setting may limit generalizability.
Evidence Library
Build your evidence library
Save research, organize studies, and quickly find important evidence again.
No ads. No tracking.
Focused on evidence, not advertising.
Secure & private
Your data is always protected.
Always up to date
New studies added every day.